Published in Blood on December 24, 2008
Genetics of human gene expression: mapping DNA variants that influence gene expression. Nat Rev Genet (2009) 4.05
Chemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait loci. Proc Natl Acad Sci U S A (2010) 2.43
Pharmacogenomic discovery using cell-based models. Pharmacol Rev (2009) 1.96
Heritable and non-genetic factors as variables of pharmacologic phenotypes in lymphoblastoid cell lines. Pharmacogenomics J (2010) 1.66
Lymphoblastoid cell lines in pharmacogenomic discovery and clinical translation. Pharmacogenomics (2012) 1.63
Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy. Clin Cancer Res (2009) 1.48
Population differences in microRNA expression and biological implications. RNA Biol (2011) 1.33
PACdb: a database for cell-based pharmacogenomics. Pharmacogenet Genomics (2010) 1.28
Impact of the 1000 genomes project on the next wave of pharmacogenomic discovery. Pharmacogenomics (2010) 1.12
Genome-wide meta-analysis identifies variants associated with platinating agent susceptibility across populations. Pharmacogenomics J (2011) 1.09
A genome-wide approach identifies that the aspartate metabolism pathway contributes to asparaginase sensitivity. Leukemia (2010) 1.03
Population differences in the rate of proliferation of international HapMap cell lines. Am J Hum Genet (2010) 1.00
Genetic variants in cytosolic 5'-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia. J Pharmacol Exp Ther (2011) 1.00
Genome-wide local ancestry approach identifies genes and variants associated with chemotherapeutic susceptibility in African Americans. PLoS One (2011) 0.99
Genetic factors influencing cytarabine therapy. Pharmacogenomics (2009) 0.97
Chemotherapeutic-induced apoptosis: a phenotype for pharmacogenomics studies. Pharmacogenet Genomics (2011) 0.96
Use of cell lines in the investigation of pharmacogenetic loci. Curr Pharm Des (2009) 0.93
Identification of predictive markers of cytarabine response in AML by integrative analysis of gene-expression profiles with multiple phenotypes. Pharmacogenomics (2011) 0.93
Comprehensive survey of SNPs in the Affymetrix exon array using the 1000 Genomes dataset. PLoS One (2010) 0.92
Pharmacogenomics of chemotherapeutic susceptibility and toxicity. Genome Med (2012) 0.89
Identification of novel germline polymorphisms governing capecitabine sensitivity. Cancer (2012) 0.89
Population-specific common SNPs reflect demographic histories and highlight regions of genomic plasticity with functional relevance. BMC Genomics (2014) 0.88
Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients. Blood (2013) 0.87
The emerging role of microRNAs in drug responses. Curr Opin Mol Ther (2010) 0.85
The use of genomic information to optimize cancer chemotherapy. Semin Oncol (2011) 0.84
Genetic and epigenetic variants contributing to clofarabine cytotoxicity. Hum Mol Genet (2013) 0.84
Bioinformatic Resources of microRNA Sequences, Gene Targets, and Genetic Variation. Front Genet (2012) 0.84
Integrating heterogeneous high-throughput data for meta-dimensional pharmacogenomics and disease-related studies. Pharmacogenomics (2012) 0.84
Analysis of innate and acquired resistance to anti-CD20 antibodies in malignant and nonmalignant B cells. PeerJ (2013) 0.83
Protein quantitative trait loci identify novel candidates modulating cellular response to chemotherapy. PLoS Genet (2014) 0.83
An eQTL-based method identifies CTTN and ZMAT3 as pemetrexed susceptibility markers. Hum Mol Genet (2011) 0.83
Impact of genetic polymorphisms on chemotherapy toxicity in childhood acute lymphoblastic leukemia. Front Genet (2012) 0.81
RRM1 and RRM2 pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients. Pharmacogenomics (2013) 0.81
Pharmacoethnicity in Paclitaxel-Induced Sensory Peripheral Neuropathy. Clin Cancer Res (2015) 0.80
Impact of polymorphisms in drug pathway genes on disease-free survival in adults with acute myeloid leukemia. J Hum Genet (2013) 0.78
Polymorphic variation in TPMT is the principal determinant of TPMT phenotype: a meta-analysis of three genome-wide association studies. Clin Pharmacol Ther (2016) 0.78
Lymphoblastoid cell lines models of drug response: successes and lessons from this pharmacogenomic model. Curr Mol Med (2014) 0.77
A general test of association for quantitative traits in nuclear families. Am J Hum Genet (2000) 22.45
Cytogenetics in acute leukemia. Blood Rev (2004) 9.99
A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: an alternative to [3H]thymidine incorporation assay. J Immunol Methods (1994) 5.34
A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity. Proc Natl Acad Sci U S A (2007) 4.35
Evaluation of genetic variation contributing to differences in gene expression between populations. Am J Hum Genet (2008) 4.01
Gene expression profiling of pediatric acute myelogenous leukemia. Blood (2004) 3.77
Drug therapy for acute myeloid leukemia. Blood (2005) 3.74
Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group. Blood (2007) 3.11
Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach. Am J Hum Genet (2007) 3.05
Mitoferrin is essential for erythroid iron assimilation. Nature (2006) 2.99
The multifunctional GIT family of proteins. J Cell Sci (2006) 2.24
ERK1/2 MAP kinases in cell survival and apoptosis. IUBMB Life (2006) 2.24
Comparison of alamar blue and MTT assays for high through-put screening. Toxicol In Vitro (2004) 2.06
Effect of population and gender on chemotherapeutic agent-induced cytotoxicity. Mol Cancer Ther (2007) 2.05
Ethnicity and survival in childhood acute myeloid leukemia: a report from the Children's Oncology Group. Blood (2006) 1.74
Cytarabine and neurologic toxicity. J Clin Oncol (1991) 1.64
Promotion of homologous recombination and genomic stability by RAD51AP1 via RAD51 recombinase enhancement. Mol Cell (2007) 1.49
RAD51AP1 is a structure-specific DNA binding protein that stimulates joint molecule formation during RAD51-mediated homologous recombination. Mol Cell (2007) 1.43
GIT1 functions as a scaffold for MEK1-extracellular signal-regulated kinase 1 and 2 activation by angiotensin II and epidermal growth factor. Mol Cell Biol (2004) 1.42
The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia. Br J Cancer (2005) 1.41
In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia. Br J Haematol (2002) 1.37
Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants. J Pharmacol Exp Ther (2007) 1.34
GIT1 is a scaffold for ERK1/2 activation in focal adhesions. J Biol Chem (2005) 1.33
Structural analysis of the deoxycytidine kinase gene in patients with acute myeloid leukemia and resistance to cytosine arabinoside. Leukemia (1994) 1.32
Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics. Clin Cancer Res (2006) 1.30
Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia. Blood (2004) 1.20
Potential mechanisms of resistance to cytarabine in AML patients. Leuk Res (2002) 1.20
Effect of race on outcome of white and black children with acute myeloid leukemia: the St. Jude experience. Pediatr Blood Cancer (2007) 1.13
Resistance to 1-beta-D-arabinofuranosylcytosine in human T-lymphoblasts mediated by mutations within the deoxycytidine kinase gene. Cancer Res (1992) 1.09
Expression of high Km 5'-nucleotidase in leukemic blasts is an independent prognostic factor in adults with acute myeloid leukemia. Blood (2001) 1.08
Noncardiogenic pulmonary edema: an unusual and serious complication of anticancer therapy. Oncologist (2001) 1.07
Problems related to resistance to cytarabine in acute myeloid leukemia. Leuk Lymphoma (2004) 1.07
Pharmacogenomics in admixed populations. Trends Pharmacol Sci (2005) 1.04
Pir51, a Rad51-interacting protein with high expression in aggressive lymphoma, controls mitomycin C sensitivity and prevents chromosomal breaks. Mutat Res (2006) 1.04
Curing childhood acute myeloid leukemia (AML) at the half-way point: promises to keep and miles to go before we sleep. Pediatr Blood Cancer (2006) 1.03
Deoxycytidine kinase and cN-II nucleotidase expression in blast cells predict survival in acute myeloid leukaemia patients treated with cytarabine. Br J Haematol (2003) 1.00
Identification of functional single nucleotide polymorphism haplotypes in the cytidine deaminase promoter. Hum Genet (2006) 1.00
Drug resistance in childhood acute myeloid leukemia. Curr Pharm Biotechnol (2007) 1.00
Progress and controversies in the treatment of pediatric acute myelogenous leukemia. Curr Opin Hematol (2002) 0.91
Substrate cycles and drug resistance to 1-beta-D-arabinofuranosylcytosine (araC). Leuk Lymphoma (2005) 0.88
High incidence of alternatively spliced forms of deoxycytidine kinase in patients with resistant acute myeloid leukemia. Blood (2000) 0.88
Desferioxamine increases iron depletion and apoptosis induced by ara-C of human myeloid leukaemic cells. Br J Haematol (1998) 0.86
High-dose cytosine arabinoside in the treatment of acute myeloid leukaemia. Blood Rev (1997) 0.81
Cytarabine-induced pericarditis: a case report and review of the literature of the cardio-pulmonary complications of cytarabine therapy. Leuk Res (1995) 0.80
Quantitation of resistance to cytosine arabinoside by myeloid leukemic cells expressing bcl-2. Eur J Haematol (1996) 0.77
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet (2008) 30.20
A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science (2006) 27.49
Trait-associated SNPs are more likely to be eQTLs: annotation to enhance discovery from GWAS. PLoS Genet (2010) 10.75
SCAN: SNP and copy number annotation. Bioinformatics (2009) 5.96
Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev (2006) 5.08
A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity. Proc Natl Acad Sci U S A (2007) 4.35
Evaluation of genetic variation contributing to differences in gene expression between populations. Am J Hum Genet (2008) 4.01
Common variants at five new loci associated with early-onset inflammatory bowel disease. Nat Genet (2009) 3.82
Rapid growth of a hepatocellular carcinoma and the driving mutations revealed by cell-population genetic analysis of whole-genome data. Proc Natl Acad Sci U S A (2011) 3.80
Ulcerative colitis-risk loci on chromosomes 1p36 and 12q15 found by genome-wide association study. Nat Genet (2009) 3.65
Let-7 expression defines two differentiation stages of cancer. Proc Natl Acad Sci U S A (2007) 3.59
Frequency of failure to inform patients of clinically significant outpatient test results. Arch Intern Med (2009) 3.55
Genetic architecture of transcript-level variation in humans. Am J Hum Genet (2008) 3.36
Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci U S A (2008) 3.13
Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach. Am J Hum Genet (2007) 3.05
Mouse models of human AML accurately predict chemotherapy response. Genes Dev (2009) 2.75
Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol (2009) 2.47
Chemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait loci. Proc Natl Acad Sci U S A (2010) 2.43
Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target. Cancer Res (2008) 2.35
Effect of population and gender on chemotherapeutic agent-induced cytotoxicity. Mol Cancer Ther (2007) 2.05
Pharmacogenomic discovery using cell-based models. Pharmacol Rev (2009) 1.96
Identification of common genetic variants that account for transcript isoform variation between human populations. Hum Genet (2008) 1.96
Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst (2010) 1.76
MLL fusion proteins preferentially regulate a subset of wild-type MLL target genes in the leukemic genome. Blood (2011) 1.74
Mapping genes that contribute to daunorubicin-induced cytotoxicity. Cancer Res (2007) 1.73
The HapMap Resource is Providing New Insights into Ourselves and its Application to Pharmacogenomics. Bioinform Biol Insights (2008) 1.73
Genetic variants associated with carboplatin-induced cytotoxicity in cell lines derived from Africans. Mol Cancer Ther (2008) 1.67
Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol (2005) 1.63
Lymphoblastoid cell lines in pharmacogenomic discovery and clinical translation. Pharmacogenomics (2012) 1.63
A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. Cancer Res (2005) 1.62
Somatic acquisition and signaling of TGFBR1*6A in cancer. JAMA (2005) 1.59
Interpretation of digital mammograms: comparison of speed and accuracy of soft-copy versus printed-film display. Radiology (2002) 1.59
Genetic variants contributing to daunorubicin-induced cytotoxicity. Cancer Res (2008) 1.57
Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics (2003) 1.51
Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J Clin Oncol (2002) 1.50
Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy. Clin Cancer Res (2009) 1.48
Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. Clin Cancer Res (2011) 1.47
Genetic associations with coronary heart disease: meta-analyses of 12 candidate genetic variants. Gene (2013) 1.45
Genome-wide interrogation of longitudinal FEV1 in children with asthma. Am J Respir Crit Care Med (2014) 1.44
MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11. Nat Commun (2013) 1.43
Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines. Genome Biol (2014) 1.43
Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma. Nat Med (2011) 1.42
Cancer pharmacogenomics: strategies and challenges. Nat Rev Genet (2012) 1.41
SNPinProbe_1.0: a database for filtering out probes in the Affymetrix GeneChip human exon 1.0 ST array potentially affected by SNPs. Bioinformation (2008) 1.41
PXR (NR1I2): splice variants in human tissues, including brain, and identification of neurosteroids and nicotine as PXR activators. Toxicol Appl Pharmacol (2004) 1.37
Genetic architecture of microRNA expression: implications for the transcriptome and complex traits. Am J Hum Genet (2012) 1.36
Consistent deregulation of gene expression between human and murine MLL rearrangement leukemias. Cancer Res (2009) 1.35
Population differences in microRNA expression and biological implications. RNA Biol (2011) 1.33
Exprtarget: an integrative approach to predicting human microRNA targets. PLoS One (2010) 1.31
Genome-wide variation of cytosine modifications between European and African populations and the implications for complex traits. Genetics (2013) 1.31
Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial. J Clin Oncol (2007) 1.31
PACdb: a database for cell-based pharmacogenomics. Pharmacogenet Genomics (2010) 1.28
Functional genetic screen of human diversity reveals that a methionine salvage enzyme regulates inflammatory cell death. Proc Natl Acad Sci U S A (2012) 1.26
Identification of genomic regions contributing to etoposide-induced cytotoxicity. Hum Genet (2008) 1.26
Susceptibility loci involved in cisplatin-induced cytotoxicity and apoptosis. Pharmacogenet Genomics (2008) 1.26
Creating and evaluating genetic tests predictive of drug response. Nat Rev Drug Discov (2008) 1.24
Diagnostic accuracy of digital mammography in patients with dense breasts who underwent problem-solving mammography: effects of image processing and lesion type. Radiology (2003) 1.24
Variants affecting exon skipping contribute to complex traits. PLoS Genet (2012) 1.24
Inactivation of O6-alkylguanine DNA alkyltransferase as a means to enhance chemotherapy. Cancer Treat Rev (2006) 1.23
Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft. Mol Cancer Ther (2005) 1.23
Germline polymorphisms discovered via a cell-based, genome-wide approach predict platinum response in head and neck cancers. Transl Res (2011) 1.22
Beyond the HapMap Genotypic Data: Prospects of Deep Resequencing Projects. Curr Bioinform (2008) 1.19
Genetic polymorphisms in arginase I and II and childhood asthma and atopy. J Allergy Clin Immunol (2005) 1.19
Integrating Epigenomics into Pharmacogenomic Studies. Pharmgenomics Pers Med (2008) 1.18